Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

1.59
+0.14009.66%
Post-market: 1.590.00000.00%19:52 EDT
Volume:1.69M
Turnover:2.62M
Market Cap:113.15M
PE:-0.91
High:1.62
Open:1.44
Low:1.38
Close:1.45
Loading ...

Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025

THOMSON REUTERS
·
18 Feb

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

GlobeNewswire
·
18 Feb

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Simply Wall St.
·
23 Jan

Ventyx Biosciences (VTYX) Gets a Hold from H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates

TIPRANKS
·
14 Jan

Ventyx Biosciences highlights its 2025 pipeline strategy

TIPRANKS
·
14 Jan

Ventyx Biosciences: Phase 2 Trial of Vtx2735 in Participants With Recurrent Pericarditis Expected to Initiate in Jan

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences: Topline Data From Ongoing Phase 2 Biomarker Trial of Vtx3232 in Participants With Early Parkinson's Disease Expected in H1 2025

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

GlobeNewswire
·
14 Jan

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Simply Wall St.
·
10 Jan

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Simply Wall St.
·
14 Dec 2024